AstraZeneca's Imjudo combo gets EMA panel nod to treat liver, lung cancers in EU
Roland Magnusson/iStock Editorial via Getty Images


A panel of the European Medicines Agency (EMA) recommended the approval of AstraZeneca's (NASDAQ:AZN) Imjudo for treating certain types of liver and lung cancers.
The EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on for Imjudo (tremelimumab), used in combination with Imfinzi (durvalumab), as a first line therapy for adults with advanced or unresectable hepatocellular carcinoma (HCC), a type of liver cancer.

The Imjudo/Imfinzi combo for liver cancer was approved in the U.S. in October.
In addition, the CHMP recommended granting marketing authorization to tremelimumab in combination with Imfinzi and platinum-based chemotherapy as a first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) with no sensitizing EGFR mutations or ALK positive mutations.
The Imjudo (tremelimumab), Imfinzi combo for this type of lung cancer was approved in the U.S. last month.